JP7422737B2 - 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール - Google Patents

神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール Download PDF

Info

Publication number
JP7422737B2
JP7422737B2 JP2021506624A JP2021506624A JP7422737B2 JP 7422737 B2 JP7422737 B2 JP 7422737B2 JP 2021506624 A JP2021506624 A JP 2021506624A JP 2021506624 A JP2021506624 A JP 2021506624A JP 7422737 B2 JP7422737 B2 JP 7422737B2
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
disease
acid
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021506624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534099A (ja
JP2021534099A5 (https=
Inventor
ディー． バニスター，サムエル
エングルマン，エドガー
ディー． グエン，クォア
スミス，マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2021534099A publication Critical patent/JP2021534099A/ja
Publication of JP2021534099A5 publication Critical patent/JP2021534099A5/ja
Priority to JP2024004449A priority Critical patent/JP2024056694A/ja
Application granted granted Critical
Publication of JP7422737B2 publication Critical patent/JP7422737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021506624A 2018-08-06 2019-08-06 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール Active JP7422737B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024004449A JP2024056694A (ja) 2018-08-06 2024-01-16 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862714962P 2018-08-06 2018-08-06
US62/714,962 2018-08-06
PCT/US2019/045229 WO2020033359A1 (en) 2018-08-06 2019-08-06 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024004449A Division JP2024056694A (ja) 2018-08-06 2024-01-16 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール

Publications (3)

Publication Number Publication Date
JP2021534099A JP2021534099A (ja) 2021-12-09
JP2021534099A5 JP2021534099A5 (https=) 2022-08-12
JP7422737B2 true JP7422737B2 (ja) 2024-01-26

Family

ID=69413327

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506624A Active JP7422737B2 (ja) 2018-08-06 2019-08-06 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール
JP2024004449A Pending JP2024056694A (ja) 2018-08-06 2024-01-16 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024004449A Pending JP2024056694A (ja) 2018-08-06 2024-01-16 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール

Country Status (13)

Country Link
US (3) US12195432B2 (https=)
EP (1) EP3833344A4 (https=)
JP (2) JP7422737B2 (https=)
KR (1) KR20210068399A (https=)
CN (2) CN112805000A (https=)
AU (1) AU2019319745B2 (https=)
BR (1) BR112021002165A2 (https=)
CA (1) CA3108773A1 (https=)
IL (3) IL307972A (https=)
MX (2) MX2021001456A (https=)
SG (1) SG11202101285YA (https=)
TW (1) TWI904076B (https=)
WO (1) WO2020033359A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210068399A (ko) 2018-08-06 2021-06-09 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 신경퇴행성 질병의 치료를 위한 피피에이알지씨1알파 활성제로서 2-아릴벤즈이미다졸
WO2021181364A1 (en) * 2020-03-13 2021-09-16 Biorchestra Co., Ltd. Diagnostic methods using pgc-1α expression
CN112933232A (zh) * 2021-02-02 2021-06-11 袁玉佳 PGC-1α激活TFEB介导的自噬在制备治疗急性肾损伤的药物中的应用
EP4426295A1 (en) * 2021-11-02 2024-09-11 Tranquis Therapeutics, Inc. Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype
US20250262189A1 (en) * 2022-04-22 2025-08-21 Rdiscovery, LLC Treatment of diseases associated with reductive stress
KR20250144994A (ko) * 2022-11-18 2025-10-13 사토시 고조 Zln-005 및 관련 화합물의 용도
WO2024118936A1 (en) * 2022-12-02 2024-06-06 Tranquis Therapeutics, Inc. 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540586A (ja) 2005-05-18 2008-11-20 フォルシュングスフェアブント ベルリン エー ファウ Ａｋａｐ−ｐｋａ相互作用の非ペプチド阻害剤
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
US20120245166A1 (en) 2009-10-15 2012-09-27 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
JP2014503527A (ja) 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
US20160074367A1 (en) 2013-04-29 2016-03-17 The General Hospital Corporation Amyloid precursor protein mrna blockers for treating down sydnrome and alzheimer's disease
WO2016180472A1 (en) 2015-05-11 2016-11-17 Kancera Ab Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity
JP2019505500A (ja) 2015-12-22 2019-02-28 カンセラ・アクチエボラグ 哺乳類ヒストンデアセチラーゼ活性の阻害剤として有用な二環式ヒドロキサム酸

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL275435A (https=) * 1961-03-01
FR1569337A (https=) * 1968-06-18 1969-05-30
US4038396A (en) * 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
GB1584296A (en) 1976-12-07 1981-02-11 Kanebo Ltd 2-substituted benzimidazole compounds
NZ234564A (en) * 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
DE3830060A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5552426A (en) 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
JPH09169729A (ja) * 1995-12-19 1997-06-30 Green Cross Corp:The 非ペプチド型インターロイキン８拮抗剤
JP4373497B2 (ja) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
JP2000143635A (ja) * 1998-06-10 2000-05-26 Takeda Chem Ind Ltd 血管新生阻害剤
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
IL142917A0 (en) * 1998-11-03 2002-04-21 Basf Ag Substituted 2-phenylbenzimidazoles, the production thereof and their use
WO2002046168A1 (en) * 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
WO2005113523A1 (en) * 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
AU2005264998A1 (en) 2004-06-17 2006-01-26 Wyeth The present invention relates to methods of making Gonadotropin Releasing Hormone ('GnRH') (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists
ES2344275T3 (es) 2005-07-28 2010-08-23 Intervet International Bv Nuevos (tio) carbamatos de benzimidazol con actividad antiparasitaria y sintesis de ellos.
DK1910384T3 (da) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
ATE523497T1 (de) 2006-11-15 2011-09-15 High Point Pharmaceuticals Llc Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
GB0807103D0 (en) * 2008-04-18 2008-05-21 Univ Bradford The Compounds
JP2012529449A (ja) * 2009-06-11 2012-11-22 シエナ ビオテク ソシエタ ペル アチオニ ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用
KR20120115252A (ko) * 2009-11-06 2012-10-17 벤더르빌트 유니버시티 Ｍｇｌｕｒ4 알로스테릭 강화제로서 아릴 및 헤테로아릴 설폰, 조성물 및 신경 기능이상을 치료하는 방법
GB201009656D0 (en) * 2010-06-09 2010-07-21 Univ St Andrews Carboxylation catalysts
JP5083393B2 (ja) 2010-09-16 2012-11-28 カシオ計算機株式会社 画像表示装置及びプログラム
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
US20150216168A1 (en) * 2012-09-05 2015-08-06 Bayer Cropscience Ag Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress
KR101435496B1 (ko) * 2012-10-22 2014-08-28 한국과학기술연구원 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체
GB201302927D0 (en) * 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
CN103113307B (zh) * 2013-02-27 2015-08-05 南京大学 苯并咪唑类化合物及其应用
CA3000985C (en) 2014-10-14 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Method for treating neurodegenerative diseases
CN104873500A (zh) 2015-04-29 2015-09-02 中国人民解放军第四军医大学 化合物zln005的用途
AU2016371598B2 (en) * 2015-12-15 2021-05-13 The Board Of Trustees Of The Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
KR20210068399A (ko) 2018-08-06 2021-06-09 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 신경퇴행성 질병의 치료를 위한 피피에이알지씨1알파 활성제로서 2-아릴벤즈이미다졸

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540586A (ja) 2005-05-18 2008-11-20 フォルシュングスフェアブント ベルリン エー ファウ Ａｋａｐ−ｐｋａ相互作用の非ペプチド阻害剤
US20120245166A1 (en) 2009-10-15 2012-09-27 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
JP2014503527A (ja) 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
US20160074367A1 (en) 2013-04-29 2016-03-17 The General Hospital Corporation Amyloid precursor protein mrna blockers for treating down sydnrome and alzheimer's disease
WO2016180472A1 (en) 2015-05-11 2016-11-17 Kancera Ab Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity
JP2019505500A (ja) 2015-12-22 2019-02-28 カンセラ・アクチエボラグ 哺乳類ヒストンデアセチラーゼ活性の阻害剤として有用な二環式ヒドロキサム酸

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUN, W. et al.，In vitro and in vivo metabolite identification of a novel benzimidazol compound ZLN005 by liquid chromatography/tandem mass spectrometry，Rapid Communications in Mass Spectrometry，2018年01月15日，Vol. 32, No. 6，pp. 480-488

Also Published As

Publication number Publication date
BR112021002165A2 (pt) 2021-05-04
EP3833344A4 (en) 2022-07-06
US20210061769A1 (en) 2021-03-04
SG11202101285YA (en) 2021-03-30
CA3108773A1 (en) 2020-02-13
US20210300877A1 (en) 2021-09-30
IL298535B2 (en) 2024-03-01
US10851066B2 (en) 2020-12-01
IL307972A (en) 2023-12-01
TW202019410A (zh) 2020-06-01
AU2019319745B2 (en) 2025-06-26
MX2021001456A (es) 2021-05-27
US11111217B2 (en) 2021-09-07
EP3833344A1 (en) 2021-06-16
MX2023012694A (es) 2023-11-21
TWI904076B (zh) 2025-11-11
JP2024056694A (ja) 2024-04-23
IL280664A (en) 2021-03-25
US12195432B2 (en) 2025-01-14
IL298535A (en) 2023-01-01
CN112805000A (zh) 2021-05-14
KR20210068399A (ko) 2021-06-09
IL280664B2 (en) 2023-04-01
IL280664B (en) 2022-12-01
JP2021534099A (ja) 2021-12-09
CN119033775A (zh) 2024-11-29
IL298535B1 (en) 2023-11-01
WO2020033359A1 (en) 2020-02-13
AU2019319745A1 (en) 2021-03-25
US20200299244A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
JP7422737B2 (ja) 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール
KR100814599B1 (ko) 신경퇴행성 장애 치료용 이미다졸 화합물
KR101345473B1 (ko) 헤테로 화합물
JP6392382B2 (ja) ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体調節因子としての２，５−ジオキソイミダゾリジン−１−イル−３−フェニル尿素誘導体
JP2010523725A (ja) 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン
UA109802C2 (xx) Похідні біцикло$3.2.1]октиламіду та їх застосування
KR20050070046A (ko) 퇴행성신경 장애 치료를 위한 티아졸 화합물
JP7376358B2 (ja) オピオイド受容体調節因子としての多環式アミン
KR102386815B1 (ko) S1p3 길항제
KR20190086445A (ko) Dyrk1 억제제로서의 벤조사이아졸 유도체
JP2025517688A (ja) Ｌｒｒｋ２阻害剤
JP2024520758A (ja) Ｔｔｂｋ１の阻害剤
WO2026002203A1 (zh) 组织蛋白酶c抑制剂化合物及其应用
CN121930231A (zh) 稠环化合物、包含其的药物组合物及其制备方法和用途
KR20240132300A (ko) Kv7 채널 활성제로서 피라졸로[1,5-a]피리딘-2,3-일 아미드

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240116

R150 Certificate of patent or registration of utility model

Ref document number: 7422737

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150